BIOMAT Database Logo BIOMAT Database Logo

Effect of cyclosporin A and the platelet-activating factor (PAF) antagonist, BN 52021, on PAF- and antigen- induced bronchoconstriction in the guinea-pig. 1989

C Touvay, and B Vilain, and V Lejeune, and J M Mencia-Huerta, and P Braquet
Department of Immunology, Institut Henri Beaufour, Les Ulis, France.

The effects of the PAF antagonist, BN 52021, and cyclosporin A (CsA), either alone or in combination, on PAF- and antigen- induced bronchoconstriction were investigated in control and passively sensitized guinea-pigs, respectively. Although single administration of CsA alone has no effect on the PAF-induced bronchoconstriction, a marked inhibition of this phenomenon is observed when the drug is given along with an inactive dose of BN 52021. This effect of the association of the two drugs on the bronchoconstriction is also related to an action on the PAF-induced alterations in the number of leukocytes and platelets. In addition, administration of CsA for 48 hrs, which alone does not influence PAF-induced bronchoconstriction, markedly increases the inhibition evoked by BN 52021. Although bolus administration of CsA has no effect on the antigen -induced bronchoconstriction, a marked inhibition of this phenomenon is observed when the drug is given for 2 days. This inhibition by CsA is not further enhanced when the animals are also treated with BN 52021. These results strengthen the hypothesis that PAF and the immune system are involved in the regulation of bronchopulmonary reactions.

UI MeSH Term Description Entries
D007116 Immunization, Passive Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER). Convalescent Plasma Therapy,Immunoglobulin Therapy,Immunotherapy, Passive,Normal Serum Globulin Therapy,Passive Antibody Transfer,Passive Transfer of Immunity,Serotherapy,Passive Immunotherapy,Therapy, Immunoglobulin,Antibody Transfer, Passive,Passive Immunization,Therapy, Convalescent Plasma,Transfer, Passive Antibody
D007783 Lactones Cyclic esters of hydroxy carboxylic acids, containing a 1-oxacycloalkan-2-one structure. Large cyclic lactones of over a dozen atoms are MACROLIDES. Lactone
D007970 Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000). Leukocytopenia,Leukocytopenias,Leukopenias
D008297 Male Males
D010972 Platelet Activating Factor A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION. AGEPC,Acetyl Glyceryl Ether Phosphorylcholine,PAF-Acether,Phosphorylcholine, Acetyl Glyceryl Ether,1-Alkyl-2-acetyl-sn-glycerophosphocholine,Platelet Aggregating Factor,Platelet Aggregation Enhancing Factor,Platelet-Activating Substance,Thrombocyte Aggregating Activity,1 Alkyl 2 acetyl sn glycerophosphocholine,Aggregating Factor, Platelet,Factor, Platelet Activating,PAF Acether,Platelet Activating Substance
D001985 Bronchial Provocation Tests Tests involving inhalation of allergens (nebulized or in dust form), nebulized pharmacologically active solutions (e.g., histamine, methacholine), or control solutions, followed by assessment of respiratory function. These tests are used in the diagnosis of asthma. Allergen Bronchial Provocation Tests,Allergen Challenge, Endobronchial,Antigen Bronchial Provocation Tests,Bronchial Allergen Challenge,Bronchial Challenge Tests,Inhalation Provocation Tests,Provocation Tests, Bronchial,Endobronchial Challenge Tests,Allergen Challenge, Bronchial,Allergen Challenges, Bronchial,Allergen Challenges, Endobronchial,Bronchial Allergen Challenges,Bronchial Challenge Test,Bronchial Provocation Test,Challenge Test, Bronchial,Challenge Test, Endobronchial,Challenge Tests, Bronchial,Challenge Tests, Endobronchial,Challenge, Bronchial Allergen,Challenge, Endobronchial Allergen,Challenges, Bronchial Allergen,Challenges, Endobronchial Allergen,Endobronchial Allergen Challenge,Endobronchial Allergen Challenges,Endobronchial Challenge Test,Inhalation Provocation Test,Provocation Test, Bronchial,Provocation Test, Inhalation,Provocation Tests, Inhalation,Test, Bronchial Challenge,Test, Bronchial Provocation,Test, Endobronchial Challenge,Test, Inhalation Provocation,Tests, Bronchial Challenge,Tests, Bronchial Provocation,Tests, Endobronchial Challenge,Tests, Inhalation Provocation
D001986 Bronchial Spasm Spasmodic contraction of the smooth muscle of the bronchi. Bronchospasm,Bronchial Spasms,Bronchospasms,Spasm, Bronchial,Spasms, Bronchial
D003524 Cyclosporins A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection. Cyclosporines
D004224 Diterpenes Twenty-carbon compounds derived from MEVALONIC ACID or deoxyxylulose phosphate. Diterpene,Diterpenes, Cembrane,Diterpenes, Labdane,Diterpenoid,Labdane Diterpene,Norditerpene,Norditerpenes,Norditerpenoid,Cembranes,Diterpenoids,Labdanes,Norditerpenoids,Cembrane Diterpenes,Diterpene, Labdane,Labdane Diterpenes
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea

Related Publications

C Touvay, and B Vilain, and V Lejeune, and J M Mencia-Huerta, and P Braquet
Inhibitory effects of a novel platelet activating factor (PAF) antagonist (BN 52021) on antigen-induced prostaglandin and thromboxane formation by the guinea pig lung.
August 1986, Pharmacological research communications,
C Touvay, and B Vilain, and V Lejeune, and J M Mencia-Huerta, and P Braquet
Effects of platelet activating factor (PAF) and its receptor antagonist BN 52021 on isolated perfused guinea-pig heart.
December 1989, Prostaglandins, leukotrienes, and essential fatty acids,
C Touvay, and B Vilain, and V Lejeune, and J M Mencia-Huerta, and P Braquet
Platelet-activating factor (PAF)-induced cardiopulmonary dysfunctions and their reversal with a PAF antagonist (BN 52021) in strain 13 guinea pigs.
July 1993, Journal of lipid mediators,
C Touvay, and B Vilain, and V Lejeune, and J M Mencia-Huerta, and P Braquet
Effect of BN 52021, a platelet activating factor antagonist, on dithranol-induced inflammation.
April 1990, The British journal of dermatology,
C Touvay, and B Vilain, and V Lejeune, and J M Mencia-Huerta, and P Braquet
Effects of intrastriatal injections of platelet-activating factor and the PAF antagonist BN 52021 on memory.
September 1996, Neurobiology of learning and memory,
C Touvay, and B Vilain, and V Lejeune, and J M Mencia-Huerta, and P Braquet
Effect of the platelet-activating factor (PAF) antagonist, BN 52021, on free radical-induced intestinal ischemia-reperfusion damage in the rat.
January 1990, Advances in experimental medicine and biology,
C Touvay, and B Vilain, and V Lejeune, and J M Mencia-Huerta, and P Braquet
Release of eicosanoids in rat peritoneal cavity stimulated with platelet-activating factor (PAF). Effect of the PAF-antagonist BN-52021.
July 1989, Prostaglandins, leukotrienes, and essential fatty acids,
C Touvay, and B Vilain, and V Lejeune, and J M Mencia-Huerta, and P Braquet
Role of platelet-activating factor (PAF) in the ovoimplantation in the rat: effect of the specific PAF-acether antagonist, BN 52021.
February 1988, Prostaglandins,
C Touvay, and B Vilain, and V Lejeune, and J M Mencia-Huerta, and P Braquet
Interference of BN 52021, a PAF-acether antagonist, with endotoxin-induced hypotension in the guinea-pig.
August 1986, Pharmacological research communications,
C Touvay, and B Vilain, and V Lejeune, and J M Mencia-Huerta, and P Braquet
Cellular electrophysiological effects of platelet-activating factor (PAF) and its antagonist BN 52021 in cardiac preparations.
January 1992, Drugs under experimental and clinical research,
Copied contents to your clipboard!